Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Neoplasm Metastasis 5Lymphoma 4Breast Neoplasms 4Ovarian Neoplasms 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Endometrial Neoplasms 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Colonic Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid cancer, follicular 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Magnetic Resonance Spectroscopy 5trametinib 4Vemurafenib 4selpercatinib 3dabrafenib 3Specimen Handling 3entrectinib 2cobimetinib 2cabozantinib 2X-Rays 2Iodine-131 2Interviews as Topic 2tremelimumab 1tovorafenib 1spartalizumab 1pembrolizumab 1omipalisib 1lenvatinib 1gallium Ga 68 dotatate 1durvalumab 1copanlisib 1Whole Body Imaging 1Transurethral Resection of Prostate 1Thyrotropin Alfa 1Surveys and Questionnaires 1Sodium Iodide 1Robotic Surgical Procedures 1Postoperative Period 1Phantoms, Imaging 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Cancer, Papillary × copanlisib × 1 year × Clear all
NCT04462471 2025-09-08

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
8 enrolled 8 charts
EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡